![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The acquisition will facilitate DSM to anticipate in the rapidly extension of the availability of Lacteol (lactobacillus LB), an effective postbiotic treatment for diarrhea, engineered using adare's innovative microbiome technology platform, for people through its B2C unit.
Lead Product(s): Lactobacillus LB
Therapeutic Area: Gastroenterology Product Name: Lacteol
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Royal DSM
Deal Size: $302.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 19, 2023